Frisell A, Lagergren J, Halle M, de Boniface J
Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 77, Solna, Stockholm, Sweden.
Department of Surgery, Capio St. Göran's Hospital, Stockholm, Sweden.
Breast Cancer Res Treat. 2020 Dec;184(3):977-984. doi: 10.1007/s10549-020-05911-z. Epub 2020 Sep 12.
The aim of the current study was to evaluate risk factors and timing of revision surgery following immediate implant-based breast reconstruction (IBR).
This retrospective cohort included women with a previous therapeutic mastectomy and implant-based IBR who had undergone implant revision surgery between 2005 and 2015. Data were collected by medical chart review and registered in the Stockholm Breast Reconstruction Database. The primary endpoint was implant removal due to surgical complications, i.e. implant failure.
The cohort consisted of 475 women with 707 revisions in 542 breasts. Overall, 33 implants were removed due to complications. The implant failure rate (4.7%) was lower without RT (2.4%) compared to RT administered after mastectomy (7.5%) and prior to IBR (6.5%) (p = 0.007). While post-mastectomy RT (OR 3.39, 95% CI 1.53-7.53), smoking (OR 3.90, 95% CI 1.76-8.65) and diabetes (OR 5.40, 95% CI 1.05-27.85) were confirmed as risk factors, time from completion of RT (> 9 months, 6-9 months, < 6 months) was not (OR 3.17, 95% CI 0.78-12.80, and OR 0.74, 95% CI 0.20-2.71). Additional risk factors were a previous axillary clearance (OR 4.91, 95% CI 2.09-11.53) and a history of a post-IBR infection (OR 15.52, 95% CI 4.15-58.01, and OR 12.93, 95% CI 3.04-55.12, for oral and intravenous antibiotics, respectively).
Previous axillary clearance and a history of post-IBR infection emerged as novel risk factors for implant failure after revision surgery. While known risk factors were confirmed, time elapsed from RT completion to revision surgery did not influence the outcome in this analysis.
本研究旨在评估即刻植入式乳房重建(IBR)后翻修手术的风险因素及时机。
这项回顾性队列研究纳入了曾接受治疗性乳房切除术并进行了植入式IBR且在2005年至2015年间接受了植入物翻修手术的女性。通过病历审查收集数据并登记在斯德哥尔摩乳房重建数据库中。主要终点是因手术并发症即植入物失败而取出植入物。
该队列由475名女性组成,共对542个乳房进行了707次翻修。总体而言,33个植入物因并发症而被取出。与乳房切除术后放疗(7.5%)和IBR术前放疗(6.5%)相比,未进行放疗时的植入物失败率(4.7%)较低(2.4%)(p = 0.007)。虽然乳房切除术后放疗(比值比3.39,95%置信区间1.53 - 7.53)、吸烟(比值比3.90,95%置信区间1.76 - 8.65)和糖尿病(比值比5.40,95%置信区间1.05 - 27.85)被确认为风险因素,但放疗结束后的时间(> 9个月、6 - 9个月、< 6个月)并非如此(比值比3.17,95%置信区间0.78 - 12.80,以及比值比0.74,95%置信区间0.20 - 2.71)。其他风险因素包括既往腋窝清扫术(比值比4.91,95%置信区间2.09 - 11.53)以及IBR后感染史(口服和静脉使用抗生素时,比值比分别为15.52,95%置信区间4.15 - 58.01和比值比12.93,95%置信区间3.04 - 55.12)。
既往腋窝清扫术和IBR后感染史是翻修手术后植入物失败的新风险因素。虽然已知风险因素得到了证实,但在本分析中,从放疗结束到翻修手术的时间间隔并未影响结果。